The decrease in CarnoSyn ® beta-alanine royalty, licensing, and raw material sales revenue during the second quarter of fiscal 2025 was primarily due to a decrease in orders from existing customers.

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

The new system printed a 27-foot-tall architectural demonstration project in Austin. Altogether, Icon's systems have printed ...

ICON, which builds homes using 3D printing, has closed on $56 million in Series C funding co-led by Norwest Venture Partners ...

The Janus Henderson Global Sustainable Equity Managed Account Portfolio returned -5.71% (gross) for Q4 2024. Click here to ...

Norwegian financial watchdog Finanstilsynet has identified “material errors and omissions” in the accounts of bulker owner ...